Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer - Geyer, CE, jr.; Garber, JE; Gelber, RD (Ann Oncol, 2022)